Polymer-Conjugated Liposomes for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Phospholipid liposomes face limitations such as limited targeting ability, stability in circulation, potential toxicity, and inability to extravasate, which hinder their effectiveness in drug delivery and therapeutic applications.
Innovation Solution
The development of polymer-conjugated liposomes, specifically those incorporating glycosaminoglycan-conjugated lipids, which enhance stability, targeting, and retention in circulation by forming a lipid bilayer with polymer-conjugated lipids, improving their structural integrity and functional efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If phospholipid liposomes are used for drug delivery, then they can encapsulate both hydrophilic and lipophilic drugs, but they have limited targeting ability and stability in circulation
Solution Approach 1:
The patent applies composite materials by combining phospholipids with polymer-conjugated lipids to form mixed liposomes. The phospholipid component provides drug encapsulation capability for both hydrophilic and lipophilic drugs, while the polymer-conjugated lipid component enhances targeting ability and circulation stability through the attached polymer moieties (such as PEG or targeting ligands), thus resolving the contradiction between versatility and reliability
Solution Approach 2:
The patent applies local quality by modifying only the surface portion of the liposome with polymer-conjugated lipids while maintaining the bulk phospholipid structure for drug encapsulation. This allows the liposome to retain its drug loading capacity while the surface-modified regions provide enhanced targeting and stability functions
2Duration of action of moving object
If phospholipid liposomes are used for sustained-release drug delivery, then drug efficacy is improved, but they exhibit potential toxicity upon chronic administration
Solution Approach 1:
The patent applies parameter changes by modifying the chemical composition parameters of the liposome, specifically incorporating polymer-conjugated lipids with different molecular weights, polymer types (PEG, targeting ligands), and conjugation ratios. These parameter changes maintain the sustained-release capability while reducing toxicity through improved biocompatibility and reduced immunogenicity of the polymer-modified surface
3Length of moving object
If small liposomes smaller than 100 nm are used for selective delivery to target systems, then they can extravasate through enlarged intercellular space in inflamed tissues, but they have limited retention and stability in circulation
Solution Approach 1:
The patent applies composite materials by creating mixed liposomes where small phospholipid cores (maintaining size <100 nm for extravasation) are combined with polymer-conjugated lipids that provide circulation stability. The polymer moieties (particularly PEG chains) create a protective corona that reduces opsonization and extends circulation half-life, thus resolving the contradiction between small size for tissue penetration and stability for circulation retention
Data Source
AI summary
The present invention provides liposomes comprising a lipid bilayer and a polymer-conjugated lipid, wherein said polymer-conjugated lipid is incorporated into said lipid bilayer. The present invention also provides methods of producing the liposomes as well as a method of delivering a nucleic acid to a subject comprising the step of administering said nucleic acid encapsulated in a mixed liposome, a method for performing diagnostic imaging in a subject, comprising the step of administering a diagnostic agent encapsulated in a mixed liposome, and methods for treating, inhibiting, or suppressing a pathological condition in a subject comprising administering to said subject a mixed liposome.